A patient with chronic liver disease is receiving Aldactone. What is the primary rationale for this prescription?

Choice A reason: Spironolactone (Aldactone) is a potassium-sparing diuretic and does not have a physiological role in the production or excretion of bile. Jaundice is managed by treating the underlying liver pathology or biliary obstruction, not through the administration of aldosterone antagonists. Choice B reason: Clotting factors are proteins synthesized by hepatocytes. Spironolactone does not influence the biosynthetic pathways of the liver and therefore has no impact on the production of fibrinogen, prothrombin, or other coagulation factors. Bleeding risks in liver disease are managed with Vitamin K or blood products. Choice C reason: Albumin production is a function of the liver's biosynthetic capacity. Spironolactone is used to manage the symptoms of low albumin (such as edema and ascites) by promoting fluid excretion, but it does not stimulate the liver to produce more protein. Only improved liver function or transplant can restore albumin levels. Choice D reason: Patients with cirrhosis often have hyperaldosteronism, where the kidneys retain sodium and water. Spironolactone is an aldosterone antagonist that blocks these receptors in the distal tubule. This promotes the excretion of sodium and water while retaining potassium, effectively reducing the ascites and edema characteristic of chronic liver disease.